Table 2. Summary of Grade 3 and Grade 4 Adverse Events in Patients Treated With Vatalanib and Everolimus From Both the Dose-Escalation and Dose-Expansion Cohorts.
Adverse Event | No. (%) | Grade |
---|---|---|
Fatigue | 7 (22.6) | 3 |
Hypertriglyceridemia | 3 (9.7) | 3 |
Diarrhea | 3 (9.7) | 3 |
Anorexia | 2 (6.5) | 3 |
Hypercholesterolemia | 2 (6.5) | 3/4 |
Rash | 2 (6.5) | 3 |
Thrombocytopenia | 2 (6.5) | 3 |
Arrhythmia | 1 (3.2) | 3 |
Hypercalcemia | 1 (3.2) | 3 |
Elevated Alkaline Phosphatase | 1 (3.2) | 3 |
Mucositis | 1 (3.2) | 3 |
Nausea | 1 (3.2) | 3 |
Neutropenia | 1 (3.2) | 3 |
Pain, Bone | 1 (3.2) | 3 |
Pain, Feet | 1 (3.2) | 3 |
Hypertension | 1 (3.2) | 4 |
Leukoencephalopathy | 1 (3.2) | 4 |
Asthenia | 1 (3.2) | 3 |
Infection, Calf | 1 (3.2) | 3 |